Fully automated, cost-effective small-scale bioprocessing
Introduction
The biopharma, cell and gene therapy, and synthetic biology industries have already recognized the potential of high-throughput automated methodologies to accelerate process development. These methodologies are well-established, particularly in drug discovery and cell line development. However, a significant bottleneck persists in process development because current small-scale high-throughput bioreactor systems fall short in key areas such as customizable automation, advanced digitalization, seamless integration of online PAT for CPP and CQA analysis, and the ability to incorporate DSP operations. Additionally, the high costs of many of these systems limit their accessibility to a broader range of users.
In this webinar, Securecell’s CEO and Head of Innovation, Carlo Andretta, unveiled the Integra1 64, a cutting-edge high-throughput bioprocessing system. This platform is designed to fully automate process development, addressing the key limitations of current technologies and setting a new standard for efficiency and innovation in the field.
If you are already heavily invested in a high-throughput bioreactor solution, we also introduced a disruptive alternative technology: the SampleBus. This innovation seamlessly integrates existing high-throughput installations into an advanced automation workflow, enhancing the capabilities of your current system.
Duration: 60 Min
Please complete the request form and we will email you the link to watch the webinar.
Request Form:
